任申 (Renshenjian) 通过HIF-1α/SPTLC2通路缓解糖尿病,通过向胺合成来缓解糖尿病
Huien Chen1, Shifei Nong1, Hongwei Huang1
1Guangdong Pharmaceutical University, Guangzhou, 510006, PR China; Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China; Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdong Province, School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.
Journal of ethnopharmacology
|May 2, 2025
概括
任申 (Renshenjian) (RSJ) 通过降低血糖和脂质,改善2型糖尿病. 它通过HIF-1α/SPTLC2通路抑制胺的产生,有利于肝脏健康和胰岛素敏感性.
科学领域:
- 综合医学是一个整体的医学.
- 代谢学 代谢学 代谢学
- 分子生物学分子生物学
背景情况:
- 仙 (Renshenjian decoction,简称RSJ) 是一种传统的中药,用于治疗糖尿病.
- 它对糖尿病的治疗机制尚不清楚.
研究的目的:
- 为了研究RSJ对小鼠2型糖尿病 (T2DM) 的影响.
- 阐明RSJ作用的潜在分子机制.
主要方法:
- 通过高脂肪饮食和 estreptozotocin 诱导的T2DM小鼠模型.
- 生物化学,组织病理学,分子对接,代谢学和分子生物学分析.
- 使用HIF-1α稳定剂DMOG的验证.
主要成果:
- 在T2DM小鼠中,RSJ改善了胰岛素敏感性,降低了血糖和脂质.
- 代谢学确定了脂体代谢作为一个关键途径.
- RSJ降低了肝脏的HIF-1α,SPTLC2表达和胺水平.
结论:
- 通过抑制胺合成,RSJ可以改善T2DM,失脂症和肝损伤.
- HIF-1α/SPTLC2通路是RSJ抗糖尿病作用的关键目标.
相关概念视频
01:58Cell Specific Gene Expression
13.3K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
142
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
142